---
title: FDA Guidance Documents
---

# FDA Guidance Documents

FDA guidance documents represent the agency's current thinking. They are not legally binding but provide important direction.

::: tip Source
[FDA Guidance Documents (Federal Register)](https://www.federalregister.gov/agencies/food-and-drug-administration) · [510(k) Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm)
:::

## Software & Digital Health
| Guidance | Year |
|----------|------|
| [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.federalregister.gov/documents/2023/09/27/2023-21093/cybersecurity-in-medical-devices-quality-system-considerations-and-content-of-premarket-submissions) | 2023 |
| [Marketing Submission Recommendations for a Predetermined Change Control Plan for AI/ML-Enabled Devices](https://www.federalregister.gov/documents/2024/12/04/2024-28275/marketing-submission-recommendations-for-a-predetermined-change-control-plan-for-artificial) | 2024 |
| [Software as a Medical Device (SaMD): Clinical Evaluation](https://www.federalregister.gov/documents/2017/01/05/2016-31957/software-as-a-medical-device-samd-clinical-evaluation) | 2017 |
| [Content of Premarket Submissions for Device Software Functions](https://www.federalregister.gov/documents/2023/06/14/2023-12723/content-of-premarket-submissions-for-device-software-functions-guidance-for-industry-and-food-and) | 2023 |

## Clinical Studies
| Guidance | Year |
|----------|------|
| [Design Considerations for Pivotal Clinical Investigations for Medical Devices](https://www.federalregister.gov/documents/2013/11/07/2013-26690/design-considerations-for-pivotal-clinical-investigations-for-medical-devices-guidance-for-industry) | 2013 |
| [Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices](https://www.federalregister.gov/documents/2017/08/31/2017-18405/use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices) | 2017 |
| [Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval](https://www.federalregister.gov/documents/2019/08/14/2019-17482/factors-to-consider-when-making-benefit-risk-determinations-in-medical-device-premarket-approval) | 2019 |

## 510(k) & De Novo
| Guidance | Year |
|----------|------|
| [510(k) Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) | — |
| [De Novo Classification Process (Evaluation of Automatic Class III Designation)](https://www.federalregister.gov/documents/2021/10/05/2021-21677/medical-device-de-novo-classification-process) | 2021 |
| [Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions](https://www.federalregister.gov/documents/2019/04/26/2019-08466/recommended-content-and-format-of-non-clinical-bench-performance-testing-information-in-premarket) | 2019 |

## Biocompatibility
| Guidance | Year |
|----------|------|
| [Use of International Standard ISO 10993-1, Biological Evaluation of Medical Devices](https://www.federalregister.gov/documents/2023/09/08/2023-19402/use-of-international-standard-iso-10993-1-biological-evaluation-of-medical-devices-part-1-evaluation) | 2023 |
